Panel · Use case · Public Affairs

Patient Advocacy Rehearsal.

LiveStakeholder Rehearsal

Rehearse a conversation with patient groups about a restrictive label with simulated advocate, clinician, brand and safety voices.

MeetingA conversation with patient advocacy groups about a restrictive label

ConstituenciesPatient advocate, clinician, brand lead, safety physician

ReaderMedical and patient engagement leads

Not askedA communications plan

DepthStandard, four seats

Patient Advocacy Rehearsal is a ready-made use case for Public Affairs. It ships under the Stakeholder Rehearsal template.

For medical affairs leads. You get each simulated constituency's position, where they conflict, the objections with proposed responses and what each would need to move. The constituencies are simulated, not consulted. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

How will a patient advocate, a treating clinician, a brand lead and a safety physician discuss a restrictive approved label with patient advocacy groups?

Who is simulated

A restrictive label limits who can be treated, and what a company may say about it is limited too. The seats are briefed on both.

Constituency simulated	What it is asked	What it works from
Patient advocate	Who is excluded by the label, what that costs, and what the group wants from the company.^{1U.S. Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making.}	Patient group statements and published submissions.
Treating clinician	Which patients fall outside the label and what alternatives exist.	Clinical guidelines.
Brand lead	What the company can say and what it cannot, and how to be honest about limits.^{2Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements.}	21 CFR 202.1 and promotion rules.
Safety physician	The safety basis for the restriction and what data could change it.	Review documents and safety data.

What the rehearsal does

Speaking honestly within the rules. The company cannot promote use outside the label. The report separates what the brand lead may say from what it must leave to medical channels.^{2Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements.}

The patient voice has a place in regulation. FDA publishes guidance on how patient experience can be incorporated into development. The report notes where the advocacy group can contribute evidence.^{1U.S. Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making.}

What would move them. The report states what each constituency would need: data, a study, access programs, or a clearer explanation.

Recommended length

Standard

Four constituencies are in the room. Standard depth gives each a seat and ends with what a rehearsal cannot tell you, in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the rehearsal checks

The rehearsal states the assumptions it makes about each constituency, and says what each gap limits. Examples for this meeting:

The advocacy group represents the patients excluded by the label.
New data could support a change in the label.
An access program is allowed under the rules that apply.

Standards, guidance and sources

Frame

FDA, patient-focused drug development guidance series.^{1U.S. Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making.}
21 CFR 202.1, Prescription-drug advertisements.^{2Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any statement that sounds like promotion beyond the label, any claim about patient preferences with no source, and any commitment the company has not approved.

What arrives

The question put, and who was simulated
The stakeholder map
Each constituency's position
Where they conflict
Objections and responses
What each would need to move, and the order to engage
What a rehearsal cannot tell you

What it will not do

The constituencies are simulated by AI specialists and are not the real people. The rehearsal prepares you for objections you can anticipate and does not predict the live room.

This is context for your review, not legal advice, and it does not replace the company’s compliance review.

It is not research with real stakeholders. The constituencies are simulated by AI specialists from stated sources, and they are not the real people.

It does not predict what the live room will say. It prepares you for the objections you can anticipate.

It does not script a response to be repeated. The responses are for you to test and to adapt.

References

[1] U.S. Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making. Known from FDA’s site; not read in full.
[2] Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements. Known from the eCFR; the text was not read in this pass.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.